Author

A. Kaiser

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Cancer Biology· 1 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Research Focus:cell type annotation· 3 Organism:human· 3 Research Focus:cell signaling & trafficking· 1 Research Focus:cell-cell communication· 1 Assay:flow cytometry· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. C. Joerger· 2 shared A. Kraemer· 2 shared A. Menge· 2 shared B.-T. Berger· 2 shared D.-I. Balourdas· 2 shared L. Elson· 2 shared L. M. Berger· 2 shared S. Knapp· 2 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

A. C. Joerger

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Development of selective pyridopyrimidin-7(8H)-one-based Mammalian STE20-like (MST3/4) kinase inhibitors

M. Rak, A. Menge, R. Tesch, L. M. Berger, D.-I. Balourdas, E. Shevchenko, A. Kraemer, L. Elson, B.-T. Berger, I. Abdi, L. M. Wahl, A. Poso, A. Kaiser, T. Hanke, T. Kronenberger, , S. Knapp

This study develops selective MST3/4 kinase inhibitors and demonstrates their distinct cellular effects compared to MST1/2 inhibition.

bioRxiv · Nov 24, 2023Biochemistry

Synthesis of pyrazole-based macrocycles leads to a highly selective inhibitor for MST3

J. A. Amrhein, L. M. Berger, D.-I. Balourdas, A. C. Joerger, A. Menge, A. Kraemer, J. M. Frischkorn, B.-T. Berger, L. Elson, A. Kaiser, M. Schubert-Zsilavecz, S. Mueller, S. Knapp, T. Hanke

The paper designs and synthesizes a macrocyclic inhibitor, JA310, that selectively targets MST3 with high potency and kinome-wide selectivity.

bioRxiv · Oct 20, 2023Biochemistry

Capitalizing on paradoxical activation of the MAPK pathway for treatment of Imatinib-resistant mast cell leukemia and chronic myelogenous leukemia

T. Wilhelm, M. A. Toledo, I. Simons, C. Stuth, V. Mohta, R. Mülfarth, M. Nitsche, K. Maschke-Neuss, S. Schmitz, A. Kaiser, M. Arock, M. Zenke, M. Huber

The paper shows that combining low-dose Ponatinib and Trametinib can overcome Imatinib resistance in mast cell leukemia by inhibiting paradoxical MAPK pathway activation.

bioRxiv · Aug 31, 2020Cancer Biology

CAR T cell entry into tumor islets is a two-step process dependent on IFNγ and ICAM-1

C. Kantari-Mimoun, S. Barrin, S. Haghiri, C. Gervais, J. Mittelstaet, N. Mockel-Tenbrinck, A. Kinkhabwala, D. Damotte, A. Lupo, M. Sibony, M. Alifano, L. Vimeux, E. Dondi, N. Bercovici, A. Trautmann, , E. Donnadieu

This study shows CAR T cell entry into tumor islets occurs in two steps, requiring IFNγ and ICAM-1 for effective infiltration.

bioRxiv · May 27, 2020Immunology

Controlling the Growth of the Skin Commensal Staphylococcus epidermidis Using D-Alanine Auxotrophy

T. M. Whitfill, D. Dodds, J. L. Bose, M.-D. Dong, G. Dube, T. Grossman, A. Kaiser, K. Kulkarni, R. Leger, S. Mootien-Boyd, A. Munivar, J. Oh, M. Pestrak, K. Rajpura, A. Tikhonov, T. Turecek

This paper engineers a D-alanine auxotrophic strain of S. epidermidis that can be controlled for therapeutic use on the skin without antibiotics or resistance genes.

bioRxiv · Mar 10, 2020Microbiology